Transcutaneous immunization with heat-labile enterotoxin: Development of a needle-free vaccine patch

Expert Review of Vaccines

Volumn 6, Issue 5, 2007, Pages 809-819

  Glenn, Gregory M ^a   Flyer, David C ^a   Ellingsworth, Larry R ^a   Frech, Sarah A ^a   Frerichs, David M ^a   Seid Jr , Robert C ^a   Yu, Jianmei ^a  

^a IOMAI Corporation   (United States)

Author keywords

Immunostimulant; Langerhans' cell; Patch; Transcutaneous immunization

Indexed keywords

BACTERIAL DNA; CHOLERA TOXIN; CYTOKINE; CYTOKINE RECEPTOR AGONIST; ESCHERICHIA COLI ENTEROTOXIN; EXOTOXIN; INFLUENZA VIRUS HEMAGGLUTININ; LIPOPOLYSACCHARIDE; NICOTINE; PARACETAMOL; TETANUS TOXOID; TOLL LIKE RECEPTOR 7 AGONIST; TOLL LIKE RECEPTOR 8 AGONIST; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; CLINICAL TRIAL; DIARRHEA; DRUG DELIVERY SYSTEM; HUMAN; INFLUENZA; NONHUMAN; PRIORITY JOURNAL; REVIEW; SKIN; TRAVELLER DIARRHEA;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, CUTANEOUS; ANIMALS; BACTERIAL TOXINS; ENTEROTOXINS; ESCHERICHIA COLI PROTEINS; HUMANS; IMMUNIZATION; NEEDLES; VACCINES;

EID: 35348938134     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.6.5.809     Document Type: Review

References (72)

1. Mutsch M, Zhou W, Rhodes P et al. Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. N. Engl. J. Med. 350(9), 896-903 (2004).
2. Tamura SI, Kurata T. A proposal for safety standards for human use of cholera toxin (or Escherichia coli heat-labile enterotoxin) derivatives as an adjuvant of nasal inactivated influenza vaccine. Jpn. J. Infect. Dis. 53(3), 98-106 (2000).
3. Zurbriggen R, Metcalfe IC, Glück R, Viret J-F, Moser C. Nonclinical safety evaluation of Escherichia coli heat-labile toxin mucosal adjuvant as a component of a nasal influenza vaccine. Expert Rev. Vaccines 2(2), 295-304 (2003).
4. Holmes R, Jobling MG, Connell T. Cholera toxin and related enterotoxins of Gram-negative bacteria. In: Bacterial Toxins and Virulence Factors in Disease. Handbook of Natural Toxins. Moss J, Iglewski B, Vaughn M, Tu AT (Eds). Marcel Dekker, Inc., NY, USA 225-255 (1995).
5. Fraser SA, de Haan L, Hearn AR et al. Mutant Escherichia coli heat-labile toxin B subunit that separates toxoid-mediated signaling and immunomodulatory action from trafficking and delivery functions. Infect. Immun. 71(3), 1527-1537 (2003).
6. Hammond SA, Walwender D, Alving CR, Glenn GM. Transcutaneous immunization: T-cell responses and boosting of existing immunity. Vaccine 19, 2701-2707 (2001).
7. Guebre-Xabier M, Hammond SA, Epperson DE, Yu J, Ellingsworth L, Glenn GM. Immunostimulant patch containing heat labile enterotoxin from E. coli enhances immune responses to injected influenza vaccine through activation of skin dendritic cells. J. Virol. 77(9), 5218-5225 (2003).
8. Chandra G, Cogswell JP, Miller LR et al. Cyclic AMP signaling pathways are important in IL-1 β transcriptional regulation. J. Immunol. 155(10), 4535-4543 (1995).
9. Platzer C, Fritsch E, Elsner T, Lehmann MH, Volk HD, Prosch S. Cyclic adenosine monophosphate-responsive elements are involved in the transcriptional activation of the human IL-10 gene in monocytic cells. Eur. J. Immunol. 29(10), 3098-3104 (1999).
10. Tsai B, Gilbert JM, Stehle T, Lencer W, Benjamin TL, Rapoport TA. Gangliosides are receptors for murine polyoma virus and SV40. EMBO J. 22(17), 4346-4355 (2003).
11. Rogers TB, Snyder SH. High affinity binding of tetanus toxin to mammalian brain membranes. J. Biol. Chem. 256(5), 2402-2407 (1981).
12. Zoeteweij J-P, Epperson DE, Porter JD et al. GM1-binding deficient exotoxin is a potent non-inflammatory broad-spectrum intradermal immunoadjuvant. J. Immunol. 177(2), 1197-1207 (2006).
13. Peppoloni S, Ruggiero P, Contorni M et al. Mutants of the Escherichia coli heat-labile enterotoxin as safe and strong adjuvants for intranasal delivery of vaccines. Expert Rev. Vaccines 2(2), 285-293 (2003).
14. Guebre-Xabier M, Hammond SA, Ellingsworth LR, Glenn GM. Immunostimulant patch enhances immune responses to influenza vaccine in aged mice. J. Virol. 78(14), 7610-7618 (2004).
15. Belyakov IM, Hammond SA, Ahlers JD, Glenn GM, Berzofsky JA. Transcutaneous immunization induces mucosal CTLs and protective immunity by migration of primed skin dendritic cells. J. Clin. Invest. 113, 998-1007 (2004).
16. Ghose C, Kalsy A, Shiekh A et al. Transcutaneous immunization with Clostridium difficile toxoid A induces systemic and mucosal immune responses and toxin A neutralizing antibodies in mice. Infect. Immun. 75, 2826-2832 (2007).
17. Glenn GM, Taylor DN, Li X, Frankel S, Montemarano A, Alving CR. Transcutaneous immunization: a human vaccine delivery strategy using a patch. Nat. Med. 6(12), 1403-1406 (2000).
18. Kenney R, Yu J, Guebre-Xabier M et al. Induction of protective immunity against lethal anthrax challenge with a patch. J. Infect. Dis. 190, 774-782 (2004).
19. McKenzie R, Bourgeois AL, Frech SA et al. Transcutaneous immunization with the heat-labile toxin (LT) of enterotoxigenic Escherichia coli (ETEC): protective efficacy in a double-blind, placebo-controlled challenge study. Vaccine 25(18), 3684-3691 (2007).
20. Yu J, Cassels F, Scharton-Kersten T et al. Transcutaneous immunization using colonization factor and heat labile enterotoxin induces correlates of protective immunity for enterotoxigenic Escherichia coli. Infect. Immun. 70(3), 1056-1068 (2002).
21. Milling SW, Yrlid U, Jenkins C, Richards CM, Williams NA, MacPherson G. Regulation of intestinal immunity: effects of the oral adjuvant Escherichia coli heat-labile enterotoxin on migrating dendritic cells. Eur. J. Immunol. 37(1), 87-99 (2007).
22. Belyakov IM, Derby MA, Ahlers JD et al. Mucosal immunization with HIV-1 peptide vaccine induces mucosal and systemic cytotoxic T lymphocytes and protective immunity in mice against intrarectal recombinant HIV-vaccinia challenge. Proc. Natl Acad. Sci. USA 95(4), 1709-1714 (1998).
23. Glenn GM, Kenney RT. Mass vaccination: solutions in the skin. In: Mass Vaccination: Global Aspects -Progress and Obstacles. Plotkin SA (Ed.). Springer Verlag, Berlin-Heidelberg, Germany 247-268 (2006).
24. Egawa M, Hirao T, Takahashi M. In vivo estimation of stratum corneum thickness from water concentration profiles obtained with Raman spectroscopy. Acta Derm. Venereol. 87(1), 4-8 (2007).
25. Sandby-Moller J, Poulsen T, Wulf HC. Epidermal thickness at different body sites: relationship to age, gender, pigmentation, blood content, skin type and smoking habits. Acta Derm. Venereol. 83(6), 410-413 (2003).
26. Fitzpatrick TB. The validity and practicality of sun-reactive skin types I through VI. Arch. Dermatol. 124(6), 869-871 (1988).
27. Huzaira M, Rius F, Rajadhyaksha M, Anderson RR, Gonzalez S. Topographic variations in normal skin, as viewed by in vivo reflectance confocal microscopy. J. Invest. Dermatol. 116(6), 846-852 (2001).
28. Lock-Andersen J, Therkildsen P, de Fine Olivarius F et al. Epidermal thickness, skin pigmentation and constitutive photosensitivity. Photodermatol. Photoimmunol. Photomed. 13(4), 153-158 (1997).
29. Jakob T, Udey MC. Epidermal Langerhans cells: from neurons to nature's adjuvants. Adv. Dermatol. 14, 209-258 (1999).
30. Yu RC, Abrams DC, Alaibac M, Chu AC. Morphological and quantitative analyses of normal epidermal Langerhans cells using confocal scanning laser microscopy. Br. J. Dermatol. 131(6), 843-848 (1994).
31. van der Aar AM, Sylva-Steenland RM, Bos JD, Kapsenberg ML, de Jong EC, Teunissen MB. Loss of TLR2, TLR4, and TLR5 on Langerhans cells abolishes bacterial recognition. J. Immunol. 178(4), 1986-1990 (2007).
32. Udey MC. Cadherins and Langerhans cell immunobiology. Clin. Exp. Immunol. 107(Suppl. 1), 6-8 (1997).
33. Güereña-Burgueño F, Hall ER, Taylor DN et al. Safety and immunogenicity of a prototype enterotoxigenic Escherichia coli vaccine administered transcutaneously. Infect. Immun. 70(4), 1874-1880 (2002).
34. O'Hagan DT (Ed.). Methods in Molecular Medicine. Humana Press, Inc., NJ, USA (2000).
35. Glenn GM, Villar CP, Flyer DC et al. Safety and immunogenicity of an ETEC vaccine patch containing heat-labile toxin: use of skin pretreatment to disrupt the stratum corneum. Infect. Immun. 75(5), 2163-2170 (2007).
36. Frerichs DM, Frech SA, Flyer DC, Yu J, Glenn GM. Controlled, single-step, stratum corneum disruption as a pretreatment for immunization via a patch. Vaccine (In Press).
37. Look JL, Butler B, Al-Khalili M et al. The adjuvant patch: a universal dose sparing approach for pandemic and conventional vaccines. BioPharm International Guide to Vaccine Development & Manufacturing 20(Suppl.), 34-45 (2007).
38. Glück R, Mischler R, Durrer P et al. Safety and immunogenicity of intranasally administered inactivated trivalent virosome-formulated influenza vaccine containing Escherichia coli heat-labile toxin as a mucosal adjuvant. J. Infect. Dis. 181(3), 1129-1132 (2000).
39. Sack DA, Sack RB. Test for enterotoxigenic Escherichia coli using Y-1 adrenal cells in miniculture. Infect. Immun. 11(2), 334-336 (1975).
40. FDA Draft Guidance for Industry, Stability Testing of Drug Substances and Drug Products. Food and Drug Administration, Rockville, MD, USA (1998).
41. ICH Guidance for Industry, Q1D: Bracketing and Matrixing Designs for Stability Testing of New Drug Substances and Products. Food and Drug Administration, Rockville, MD, USA. Federal Register, 2339-2340 (2003).
42. ICH Guidance for Industry, Q1A(R2): Stability Testing of New Drug Substances and Products (Second Revision). Food and Drug Administration, Rockville, MD, USA. Federal Register, 65717-65718 (2003).
43. Lucas TI, Bishara RH, Seervers RH. A stability program for the distribution of drug products. Pharm. Technol. 2, 68-73 (2004).
44. Baca-Estrada ME, Foldvari M, Ewen C, Badea I, Babiuk LA. Effects of IL-12 on immune responses induced by transcutaneous immunization with antigens formulated in a novel lipid-based biphasic delivery system. Vaccine 18(17), 1847-1854 (2000).
45. Chen D, Erickson CA, Endres RL et al. Adjuvantation of epidermal powder immunization. Vaccine 19(20-22), 2908-2917 (2001).
46. Glenn GM, Rao M, Matyas GR, Alving CR. Skin immunization made possible by cholera toxin. Nature 391(6670), 851 (1998).
47. Scharton-Kersten T, Yu J, Vassell R, O'Hagan D, Alving CR, Glenn GM. Transcutaneous immunization with bacterial ADP-ribosylating exotoxins, subunits, and unrelated adjuvants. Infect. Immun. 68(9), 5306-5313 (2000).
48. Dickinson BL, Clements JD. Dissociation of Escherichia coli heat-labile enterotoxin adjuvanticity from ADP-ribosyltransferase activity. Infect. Immun. 63(5), 1617-1623 (1995).
49. Freytag LC, Clements JD. Bacterial toxins as mucosal adjuvants. Curr. Top. Microbiol. Immunol. 236, 215-236 (1999).
50. Michetti P, Kreiss C, Kotloff KL et al. Oral immunization with urease and Escherichia coli heat-labile enterotoxin is safe and immunogenic in Helicobacter pylori-infected adults. Gastroenterology 116(4), 804-812 (1999).
51. Snider DP. The mucosal adjuvant activities of ADP-ribosylating bacterial enterotoxins. Crit. Rev. Immunol. 15(3-4), 317-348 (1995).
52. Weltzin R, Guy B, Thomas WD Jr, Giannasca PJ, Monath TP. Parenteral adjuvant activities of Escherichia coli heat-labile toxin and its B subunit for immunization of mice against gastric Helicobacter pylori infection. Infect. Immun. 68(5), 2775-2782 (2000).
53. Neidleman JA, Ott G, O'Hagan D. Mutant heat-labile enterotoxins as adjuvants for CTL induction. In: Vaccine Adjuvants: Preparation Methods and Research Protocols. O'Hagan D (Ed.). Humana Press, Totowa, NJ, USA 327-336 (2000).
54. Porgador A, Staats HF, Faiola B, Gilboa E, Palker TJ. Intranasal immunization with CTL epitope peptides from HIV-1 or ovalbumin and the mucosal adjuvant cholera toxin induces peptide-specific CTLs and protection against tumor development in vivo. J. Immunol. 158(2), 834-841 (1997).
55. Seo N, Tokura Y, Nishijima T, Hashizume H, Furukawa F, Takigawa M. Percutaneous peptide immunization via corneum barrier-disrupted murine skin for experimental tumor immunoprophylaxis. Proc. Natl Acad. Sci. USA 97(1), 371-376 (2000).
56. Levine MM, Kaper JB, Black RE, Clements ML. New knowledge on pathogenesis of bacterial enteric infections as applied to vaccine development. Microbiol. Rev. 47(4), 510-550 (1983).
57. Dell K, Koesters R, Gissmann L. Transcutaneous immunization in mice: induction of T-helper and cytotoxic T lymphocyte responses and protection against human papillomavirus-induced tumors. Int. J. Cancer 118(2), 364-372 (2005).
58. Itoh T, Celis E. Transcutaneous immunization with cytotoxic T-cell peptide epitopes provides effective antitumor immunity in mice. J. Immunother. 28(5), 430-437 (2005).
59. Klimuk SK, Najar HM, Semple SC, Aslanian S, Dutz JP. Epicutaneous application of CpG oligodeoxynucleotides with peptide or protein antigen promotes the generation of CTL. J. Invest. Dermatol. 122(4), 1042-1049 (2004).
60. Rechtsteiner G, Warger T, Osterloh P, Schild H, Radsak MP. Priming of CTL by transcutaneous peptide immunization with imiquimod. J. Immunol. 174(5), 2476-2480 (2005).
61. Stephenson I, Zambon MC, Rudin A et al. Phase I evaluation of intranasal trivalent inactivated influenza vaccine with nontoxigenic Escherichia coli enterotoxin and novel biovector as mucosal adjuvants, using adult volunteers. J. Virol. 80(10), 4962-4970 (2006).
62. Kotloff KL, Sztein MB, Wasserman SS, Losonsky GA, DiLorenzo SC, Walker RI. Safety and immunogenicity of oral inactivated whole-cell Helicobacter pylori vaccine with adjuvant among volunteers with or without subclinical infection. Infect. Immun. 69(6), 3581-3590 (2001).
63. Frech SA, Kenney RT, Spyr CA, Lazar H, Glück R, Glenn GM. Improved immune responses to influenza vaccination in the elderly using an immunostimulant patch. Vaccine 23(7), 946-950 (2005).
64. Glenn GM, Scharton-Kersten T, Vassell R, Matyas GR, Alving CR. Transcutaneous immunization with bacterial ADP-ribosylating exotoxins as antigens and adjuvants. Infect. Immun. 67(3), 1100-1106 (1999).
65. Hammond SA, Tsonis C, Sellins K et al. Transcutaneous immunization of domestic animals: opportunities and challenges. Adv. Drug Deliv. Rev. 43, 45-55 (2000).
66. Skountzou I, Quan FS, Jacob J, Compans RW, Kang SM. Transcutaneous immunization with inactivated influenza virus induces protective immune responses. Vaccine 24(35-36), 6110-6119 (2006).
67. Glenn GM. Advanced development of antigen sparing pandemic influenza vaccines. Department of Health and Human Services Contract No. HHSO100200700031C, Washington DC, USA (2007).
68. Treanor JJ, Campbell JD, Zangwill KM, Rowe T, Wolff M. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N. Engl. J. Med. 354(13), 1343-1351 (2006).
69. Steffen R, Castelli F, Dieter Nothdurft H, Rombo L, Jane Zuckerman N. Vaccination against enterotoxigenic Escherichia coli, a cause of travelers' diarrhea. J. Travel Med. 12(2), 102-107 (2005).
70. Glenn GM, Scharton-Kersten T, Vassell R, Mallett CP, Hale TL, Alving CR. Transcutaneous immunization with cholera toxin protects mice against lethal mucosal toxin challenge. J. Immunol. 161(7), 3211-3214 (1998).
71. Glenn G, Frech S, Villar C et al. Transcutaneous immunization with the heat labile toxin (LT) of enterotoxigenic Escherichia coli (ETEC) protects in a Phase II field trial in travelers to Guatemala (GU) and Mexico (MX). Presented at: 47th Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, USA, September 17-20, 2007 (Abstract 3810).
72. Glenn GM, Alving CR. Adjuvant for transcutaneous immunization. US5980898. The United States of America as represented by the US Army Medical Research & Material Command, Washington, DC, USA (1999).